Last updated: February 23, 2026
Scope, Claims, and Patent Landscape for Australian Patent AU2009200606
Overview
Patent AU2009200606, filed by Novartis Vaccines and Diagnostics SA (a subsidiary of Novartis AG), pertains to a vaccine composition for prevention or treatment of infectious diseases, particularly those caused by pathogens like Neisseria gonorrhoeae. The patent was granted in Australia, offering patent exclusivity typically lasting 20 years from the date of filing (April 17, 2009), barring extensions.
Scope of the Patent
The patent discloses a vaccine comprising a neisseria outer membrane vesicle (OMV) with specific antigenic proteins or complexes. The scope covers:
- Vaccine compositions containing OMVs derived from Neisseria gonorrhoeae.
- Variations where the OMV includes specific antigens such as PorA, PorB, or other outer membrane proteins.
- Methods of producing the OMV-based vaccine, including steps for harvesting, purification, or formulation.
- Uses of the vaccine in preventing or treating Neisseria infections.
- Adjuvant compositions combined with the OMVs to enhance immune response.
The claims extend broadly to any vaccine composition with these components, encompassing recombinant or naturally derived OMV formulations. It also covers diagnostic methods using the OMVs and methods of producing the vaccine.
Key Patent Claims
The patent's claims can be grouped into multiple categories:
-
Vaccine Composition Claims:
- An immunogenic composition comprising OMVs derived from Neisseria gonorrhoeae.
- The inclusion of specific outer membrane proteins (e.g., PorA, PorB) within the OMV.
- The use of certain adjuvants combined with OMVs.
-
Method of Production:
- Techniques for isolating OMVs from Neisseria gonorrhoeae cultures.
- Methods for modifying or enhancing OMV preparations for vaccine use.
-
Uses and Methods:
- Use of the composition for preventing or treating gonorrhea or other Neisseria infections.
- Diagnostic methods based on the presence of OMV components in samples.
-
Variants:
- Variations in OMV composition, such as genetically modified strains producing altered outer membrane proteins.
- Formulations tailored for specific age groups or populations.
Patent Landscape
The landscape surrounding AU2009200606 involves multiple patent families and research activities globally:
Legal and Commercial Implications
- Licensing: Novartis holds the exclusive rights to commercialize this vaccine in Australia, with potential for licensing negotiations internationally.
- Patent Starvation: No significant patent barriers are expected in Australia due to expiration, facilitating research by third parties.
- Potential for Innovators: Opportunities exist to develop improved formulations or combination vaccines leveraging the foundational OMV technology disclosed.
Conclusion
AU2009200606 covers broad claims on OMV-based vaccines targeting Neisseria gonorrhoeae, including composition, production methods, and use cases. The patent landscape emphasizes global interest in bacterial OMV vaccines, with licenses, expiration, and ongoing research influencing commercial pathways.
Key Takeaways
- The patent’s claims focus on OMV-based vaccines containing specific outer membrane proteins.
- The scope encompasses vaccine composition, preparation, and use, with broad coverage of OMV variants.
- The Australian patent aligns with international patent families, primarily in the US and Europe.
- Patent expiry opens opportunities for competition or improvement in gonorrhea vaccine development.
- The landscape indicates strong ongoing R&D activity targeting resistant gonorrhea strains with OMV technology.
FAQs
1. What is the primary innovation protected by AU2009200606?
It covers OMV-based vaccine compositions derived from Neisseria gonorrhoeae, including specific outer membrane proteins, methods of production, and their use for preventing or treating gonorrhea.
2. Are there similar patents globally?
Yes, patents with comparable claims exist in the US (e.g., US20110147255A1) and Europe (e.g., EP2356294A1), indicating a broad patent family.
3. What is the patent duration and expiry?
Filed in April 2009, the patent typically expires 20 years from the filing date, around April 2029, unless extended.
4. What are the technological challenges in developing OMV vaccines for gonorrhea?
Antigenic variability among gonorrhea strains complicates broad protection, and stability issues impact vaccine shelf life and efficacy.
5. How does this patent landscape impact future development?
It provides foundational IP for OMV vaccines, with expiration potentially enabling new entrants and bearing on licensing negotiations.
References
[1] Novartis Vaccines and Diagnostics SA. (2009). AU2009200606 patent document.
[2] U.S. Patent Application No. US20110147255A1. (2011).
[3] European Patent No. EP2356294A1. (2011).
